Voluntary Groups Are Mixed On Whether Decade Of The Brain Will Boost Funding

Increased awareness and larger donations are drops in the bucket compared with the amount of federal dollars needed When President Bush signed a congressional resolution officially proclaiming the 1990s as the Decade of the Brain, a cry of triumph rose from patient advocacy groups across the country. Many of the roughly 70 voluntary organizations that represent victims of neurological and mental disorders--a number of whom raise money for research in basic neuroscience as well as for the study

Written byDiana Morgan
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

"We were thrilled," says Sue Levi-Pearl, research director of the Tourette Syndrome Association, whose 28,000 members donated $350,000 for last year's neurology research budget. "We thought there was going to be some sort of greater attention to neurological disorders [by Congress], and we looked to a major breakthrough in an understanding of brain function and human behavior as a result of the Decade of the Brain."

Now, 10 months into that decade, all she feels is disappointment.

"I've seen lots of talk and no dollars," she says. "If Congress really meant this to be the Decade of the Brain, they would have doubled or tripled the money to neurology."

Many officials of the patient advocacy groups--associations commonly known as voluntaries, which work to eradicate diseases from the relatively unknown Charcot-Marie Tooch disease to the more familiar Parkinson's disease--feel similarly disillusioned. On the one hand, they are excited about the resolution ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies